Search research articles
Contact Us
Filters
Showing results (161-170 of 432) with videos related to
Page
of 44
Sort By:
Blood Advances
|
August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
Brian Ball, Rami S Komrokji, Lionel Adès, et al.
Leukemia
|
September 5, 2025
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model
Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, et al.
British Journal of Haematology
|
February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux, Norbert Gattermann, John F Seymour, et al.
Leukemia & Lymphoma
|
December 8, 2011
Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial
Giovanna Cannas, Cécile Pautas, Emmanuel Raffoux, et al.
Leukemia Research
|
March 11, 2021
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival
Jacqueline S Garcia, Ronan T Swords, Gail J Roboz, et al.
Haematologica
|
March 15, 2006
Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
Sophie Ducastelle, Lionel Adès, Claude Gardin, et al.
Leukemia Research
|
January 4, 2019
Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes
Judith Neukirchen-Strapatsas, Heinz Tuechler, Matteo Della Porta, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 15, 2012
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine
Uwe Platzbecker, Johannes Schetelig, Jürgen Finke, et al.
Frontiers in Oncology
|
February 24, 2025
Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms
Esther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, et al.
American Journal of Hematology
|
June 27, 2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities
Anne Wanquet, Thomas Prebet, Céline Berthon, et al.
Page
of 44
Search research articles
Search
Showing results (161-170 of 432) with videos related to
Sort By:
Page
of 44
Blood Advances
|
August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
Brian Ball, Rami S Komrokji, Lionel Adès, et al.
Leukemia
|
September 5, 2025
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model
Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, et al.
British Journal of Haematology
|
February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux, Norbert Gattermann, John F Seymour, et al.
Leukemia & Lymphoma
|
December 8, 2011
Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial
Giovanna Cannas, Cécile Pautas, Emmanuel Raffoux, et al.
Leukemia Research
|
March 11, 2021
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival
Jacqueline S Garcia, Ronan T Swords, Gail J Roboz, et al.
Haematologica
|
March 15, 2006
Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
Sophie Ducastelle, Lionel Adès, Claude Gardin, et al.
Leukemia Research
|
January 4, 2019
Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes
Judith Neukirchen-Strapatsas, Heinz Tuechler, Matteo Della Porta, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 15, 2012
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine
Uwe Platzbecker, Johannes Schetelig, Jürgen Finke, et al.
Frontiers in Oncology
|
February 24, 2025
Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms
Esther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, et al.
American Journal of Hematology
|
June 27, 2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities
Anne Wanquet, Thomas Prebet, Céline Berthon, et al.
Page
of 44